Sutro Biopharma (STRO) Receives a Buy from Piper Sandler

Tip Ranks
2025.12.04 11:40
portai
I'm PortAI, I can summarize articles.

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating for Sutro Biopharma, setting a price target of $20. Despite Tenthoff's average return of -8.8% and a 33.95% success rate, Sutro Biopharma has a Moderate Buy consensus with a price target of $6.70.

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Sutro Biopharma today and set a price target of $20.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

According to TipRanks, Tenthoff is an analyst with an average return of -8.8% and a 33.95% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Arrowhead Pharmaceuticals.

Sutro Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.70.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer